Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia: Evidence for a specific serotonergic effect from a double-blind study

Journal of Clinical Psychopharmacology

Volumn 18, Issue 3, 1998, Pages 208-211

  Silver, Henry ^a   Shmugliakov, Natalie ^a  

^a Flugelman Mazra Psychiatric Hospital   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; BIPERIDEN; CHLORPROMAZINE; CLOTIAPINE; FLUPENTIXOL; FLUPHENAZINE; FLUVOXAMINE; HALOPERIDOL; LEVOMEPROMAZINE; MAPROTILINE; NEUROLEPTIC AGENT; PENFLURIDOL; PERPHENAZINE; SEROTONIN UPTAKE INHIBITOR; SULPIRIDE; THIORIDAZINE;

ADULT; AFFECT; ANHEDONIA; ARTICLE; ATTENTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HUMAN; MALE; NEGATIVE SYNDROME; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; PSYCHIATRIC TREATMENT; RATING SCALE; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; TREATMENT INDICATION; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS; DOUBLE-BLIND METHOD; FEMALE; FLUVOXAMINE; HUMANS; MALE; MAPROTILINE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, SEROTONIN; SCHIZOPHRENIA; SEROTONIN UPTAKE INHIBITORS;

EID: 0031803116     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199806000-00005     Document Type: Article

References (19)

1. Silver H, Nassar A. Fluvoxamine improves negative symptoms in treated chronic schizophrenics. An add-on double blind placebo controlled study. Biol Psychiatry 1992;31:698-704.
2. Goff DC, Midha KK, Sarid-Segal O, Hubbard JW, Amico E. A placebo controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia Psychopharmacology 1995;117:417-23.
3. Spina E, De Dominico P, Ruello C, Longobardo N, Gitto C, Ancione M, Di Rosa AE, Caputi AP. Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenia. Int Clin Psychopharmacol 1994;9:281-5.
4. Silver H, Kaplan A, Kushnir M. Fluvoxamine augmentation in chronic schizophrenia: an open exploratory study. Hum Psychopharmacol 1995;10,59-63.
5. Silver H, Kaplan A, Jahjah N. Fluvoxamine augmentation in clozapine resistant schizophrenia [letter]. Am J Psychiatry 1995; 152:1098.
6. Silver H, Kushnir M, Kaplan A. Fluvoxamine augmentation in clozapine resistant schizophrenia: an open pilot study. Biol Psychiatry 1996;40:671-4.
7. Szegedi A, Wiesner J, Hiemke C. Improved efficacy and fewer side effects under clozapine treatment after addition of fluvoxamine. J Clin Psychopharmacol 1995;15:141-3.
8. Siris SG. Depression and schizophrenia. In: Hirsch S, Weinberger DR, eds. Schizophrenia. Oxford: Blackwell Science Ltd, 1995: 128-15.
9. Blackwell B. Newer antidepressant drugs. In: Meltzer HY, ed. Psychopharmacology: the third generation of progress. New York: Raven Press, 1987:1041-50.
10. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812.
11. Andreasen NC. Scale for the Assessment of Negative Symptoms (SANS). Iowa City: University of Iowa, 1983.
12. Andreasen NC. Scale for the Assessment of Positive Symptoms (SAPS). Iowa City: University of Iowa, 1984.
13. Montgomery S, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9.
14. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand (Suppl) 1970;212:11-9.
15. Gelenberg AJ, Bassuk EL, Schoonover SC, eds. The practitioner's guide to psychoactive drugs. 3rd ed. New York: Plenum Medical Book Company, 1977:8.
16. Silver H, Jahjah N, Kushnir M. Psychotic symptoms in schizophrenics during chronic fluvoxamine treatment. Schizophr Res 1995;16:77-9.
17. Daniel DG, Randolph C, Jaskiw G, Handel S, Williams T, Abi-Dargham A, Shoaf S, Egan M, Elkashef A, Liboff S, Markku L. Coadministration of fluvoxamine increases serum concentrations of haloperidol. J Clin Psychopharmacol 1994;14:340-3.
18. Firkusny L, Gleitner H. Maprotiline metabolism appears to cosegregate with the genetically determined CYP2D6 polymorphic hydroxylation of debrisoquine. Br J Clin Pharmacol 1994 37:383-8.
19. Breier A. Serotonin schizophrenia and antipsychotic drug action Schizophr Res 1995;14:187-202.